Takeshi Sano

Dr. Takeshi Sano


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2016 in Gastric Cancer
Verified
Journal Article
Open access
PDF file
TSTakeshi Sano
Takeshi Sano
DCDaniel G. Coit
Daniel G. Coit
HKHyung Ho Kim
Hyung Ho Kim
FRFranco Roviello
Franco Roviello
PKPaulo Kassab
Paulo Kassab
YOYasuo Ohashi
Yasuo Ohashi
Background The current AJCC staging system for gastric cancer (AJCC7) incorporated several major revisions to the previous edition. The T and N categories and the stage groups were newly defined, and adenocarcinoma of the esophagogastric junction (EGJ) was reclassified and staged according to the esophageal system. Studies to validate these changes showed inconsistent results. The International Gastric Cancer Association (IGCA) launched a project to support evidence-based revisions to the next edition of the AJCC staging system. Methods Clinical and pathological data on patients who underwent curative gastrectomy at 59 institutions in 15 countries between 2000 and 2004 were retrospectively collected. Patients lost to follow-up within 5 years of surgery were excluded. Patients treated with neoadjuvant therapy were excluded. The data were analyzed in total, and separately by region of treatment. Results Of 25,411 eligible cases, 84.8 % were submitted from 24 institutions of Japan and Korea, 6.4 % from other Asian countries, and 8.8 % from 29 Western institutions. The T and N categories of AJCC7 clearly stratified the patient survival. Patients with pN3a and pN3b showed distinct prognosis in all regions, and by introducing pN3a and pN3b into a cluster analysis, we established a new stage grouping with better stratification than AJCC7, especially among stage III subgroups. Survival of Siewert type 2 and 3 EGJ tumors was better stratified by this IGCA stage grouping than by either esophageal or gastric scheme of AJCC7. Conclusions For the next revision of AJCC classification, we propose a new stage grouping based on a large, worldwide data collection.

15 May 2011 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
TSTakeshi Sano
Takeshi Sano
TATakashi Aiko
Takashi Aiko

12 May 2010 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
MIM. Inoue
M. Inoue
TSTakeshi Sano
Takeshi Sano
AKA. Kuchiba
A. Kuchiba
HTH. Taniguchi
H. Taniguchi
TFT. Fukagawa
T. Fukagawa
HKH. Katai
H. Katai

7 June 2013 in Gastric Cancer
Verified
Journal Article
Open access
PDF file
KKKoshi Kumagai
Koshi Kumagai
NYNoriko Yamamoto
Noriko Yamamoto
IMIsao Miyashiro
Isao Miyashiro
YTYasuhiko Tomita
Yasuhiko Tomita
HKHitoshi Katai
Hitoshi Katai
TSTakeshi Sano
Takeshi Sano
Background The accurate diagnosis of lymph node (LN) metastasis is important for making treatment decisions for gastric cancer patients. This multicenter study evaluated the clinical performance of the one-step nucleic acid amplification (OSNA) assay (Sysmex Corp.), an automated system that detects cytokeratin 19 (CK19) mRNA, in detecting LN metastases in gastric cancer patients. Methods LNs retrieved from patients who had undergone gastric cancer surgery at one of the four Japanese hospitals involved in this study were divided into blocks at 2-mm intervals. Alternate blocks were examined with the OSNA assay and the remaining blocks were assessed histologically. Results A total of 394 LNs from 61 patients were examined. The concordance rate between the OSNA assay and the histological examination was 0.942 (95 % CI, 0.914–0.963). Sensitivity and specificity of the OSNA assay compared to the histological examination were 0.833 (95 % CI, 0.707–0.921) and 0.959 (95 % CI, 0.932–0.977), respectively. Discordant results were observed in 23 LNs (5.8 %), and these were mainly the result of tissue allocation bias and/or low CK19 protein expression. Conclusion The OSNA assay can detect lymph node metastases in gastric cancer patients as accurately as the histological examination of blocks sectioned at 2-mm intervals. The OSNA assay is a useful tool for the intraoperative diagnosis of LN metastasis in gastric cancer patients.

4 July 2015 in Gastric Cancer
Verified
Journal Article
Open access
PDF file
GBGian Luca Baiocchi
Gian Luca Baiocchi
DDDomenico D’uGo
Domenico D’uGo
DCDaniel Coit
Daniel Coit
RHRichard Hardwick
Richard Hardwick
PKPaulo Kassab
Paulo Kassab
GMGiovanni De Manzoni
Giovanni De Manzoni
Purpose Presently, there is no scientific evidence supporting a definite role for follow-up after gastrectomy for cancer, and clinical practices are quite different around the globe. The aim of this consensus conference was to present an ideal prototype of follow-up after gastrectomy for cancer, based on shared experiences and taking into account the need to rationalize the diagnostic course without losing the possibility of detecting local recurrence at a potentially curable stage. Methods On June 19–22, 2013 in Verona (Italy), during the 10th International Gastric Cancer Congress (IGCC) of the International Gastric Cancer Association, a consensus meeting was held, concluding a 6-month, Web-based, consensus conference entitled “Rationale of oncological follow-up after gastrectomy for cancer.” Results Forty-eight experts, with a geographical distribution reflecting different health cultures worldwide, participated in the consensus conference, and 39 attended the consensus meeting. Six statements were finally approved, displayed in a plenary session and signed by the vast majority of the 10th IGCC participants. These statements are attached as an annex to the Charter Scaligero on Gastric Cancer. Conclusion After gastrectomy for cancer, oncological follow-up should be offered to patients; it should be tailored to the stage of the disease, mainly based on cross-sectional imaging, and should be discontinued after 5 years.

31 January 2017 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
TSTakeshi Sano
Takeshi Sano